金属有机框架通过屏障保护和免疫调节作用缓解DSS诱导的性结肠炎
Mubbashar Abbas1, Khan Suliman1, Min Chen2
1National Reference Laboratory of Veterinary Drug Residues (HZAU), MAO Key Laboratory for Detection of Veterinary Drug Residues, Wuhan, 430070, Hubei, China.
Biological trace element research
|February 25, 2026
概括
金属有机框架 (Co-MOF) 通过减少炎症和恢复肠道屏障完整性,证明了性结肠炎 (UC) 的显著治疗潜力. 这项研究强调了Co-MOF.
科学领域:
- 材料科学 材料科学 材料科学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 性结肠炎 (UC) 涉及过度的细胞因子产生,上皮屏障破坏和氧化应激.
- 有效的UC治疗需要免疫调节和恢复粘膜完整性.
研究的目的:
- 评估Fe-MOF,Cr-MOF和Co-MOF对性结肠炎的体内和体外治疗潜力.
- 评估这些金属有机框架 (MOF) 的免疫调节,屏障保护和抗氧化作用.
主要方法:
- 使用SEM,FTIR,XRD和ICP-MS对MOF进行表征.
- 使用LPS刺激的RAW264.7巨细胞进行了体外研究.
- 使用硫酸 (DSS) 诱导的小鼠结肠炎模型进行体内研究.
- 通过细胞毒性测定,免疫光学,ELISA,组织病理学,免疫阻塞和qPCR对MOF影响的评估.
主要成果:
- 同MOF显著降低了巨细胞和小鼠结肠中的促炎性细胞因子 (TNF-α,IL-6,IL-1β) 表达.
- 同MOF治疗改善了DSS诱导性结肠炎模型中的临床分数 (DAI),体重和结肠长度.
- 同MOF恢复了紧结蛋白 (Occludin,ZO-1),增强了抗氧化活性 (SOD,CAT),并使血细胞数量正常化,没有观察到系统性毒性.
结论:
- 与Fe-MOF和Cr-MOF相比,Co-MOF在性结肠炎的临床前模型中表现出优越的免疫调节和粘膜屏障保护作用.
- 由于其抗炎和屏障恢复性质,Co-MOF显示出作为UC治疗剂的巨大潜力.
- 需要进一步的机制验证,以充分阐明UC中Co-MOF的治疗机制.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.7K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.7K
Inflammatory Bowel Disease IV: Pharmacological Management
852
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
852
Inflammatory Bowel Disease I: Ulcerative Colitis
1.3K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
602
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
602
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.3K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.3K


